scholarly journals Plasma levels of interleukin-33 (IL-33) and soluble suppression of tumorigenicity 2 (sST2) as a potential predictive biomarker in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC) undergoing systemic chemotherapy (sCTX)

2017 ◽  
Vol 28 ◽  
pp. xi11-xi12
Author(s):  
M. Kieler ◽  
M. Unseld ◽  
S. Demyanets ◽  
D. Bianconi ◽  
G. Prager
Author(s):  
Katelyn Donahue ◽  
Wenting Du ◽  
Carlos Espinoza ◽  
Eileen Carpenter ◽  
Kristee Brown ◽  
...  

Cancers ◽  
2019 ◽  
Vol 11 (11) ◽  
pp. 1808 ◽  
Author(s):  
Jerome Raffenne ◽  
Remy Nicolle ◽  
Francesco Puleo ◽  
Delphine Le Corre ◽  
Camille Boyez ◽  
...  

Gemcitabine is still one of the standard chemotherapy regimens for pancreatic ductal adenocarcinoma (PDAC). Gemcitabine uptake into tumor cells is mainly through the human equilibrative nucleoside transport 1 (hENT1). It was therefore proposed as a potential predictive biomarker of gemcitabine efficacy but reports are conflicting, with an important heterogeneity in methods to assess hENT1 expression. A multicenter cohort of 471 patients with a resected PDAC was used to assess simultaneously the predictive value of the 2 best described hENT1 antibodies (10D7G2 and SP120). Three additional antibodies and the predictive value of hENT1 mRNA were also tested on 251 and 302 patients, respectively. hENT1 expression was assessed in 54 patients with matched primary tumors and metastases samples. The 10D7G2 clone was the only hENT1 antibody whose high expression was associated with a prolonged progression free survival and overall survival in patients who received adjuvant gemcitabine. hENT1 mRNA level was also predictive of gemcitabine benefit. hENT1 status was concordant in 83% of the cases with the best concordance in synchronous metastases. The 10D7G2 clone has the best predictive value of gemcitabine benefit in PDAC patients. Since it is not commercially available, hENT1 mRNA level could represent an alternative to assess hENT1 status.


2012 ◽  
Vol 16 (8) ◽  
pp. 1776-1791 ◽  
Author(s):  
Claus Schäfer ◽  
Hendrik Seeliger ◽  
Dominik C. Bader ◽  
Gerald Assmann ◽  
Denise Buchner ◽  
...  

2017 ◽  
Vol 28 ◽  
pp. iii71
Author(s):  
Doraid Alrifai ◽  
Styliani Germanou ◽  
Debashis Sarker ◽  
Paul J. Ross ◽  
Anna-Mary Young ◽  
...  

Oncotarget ◽  
2017 ◽  
Vol 8 (32) ◽  
pp. 52571-52583 ◽  
Author(s):  
Hongzhe Li ◽  
Xinjing Wang ◽  
Yuan Fang ◽  
Zhen Huo ◽  
Xiongxiong Lu ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document